The PPD-backed clinical trial software provider increased its overall funding to $521m in a series D round valuing it at $2.1bn.
Medable, a US-based developer of clinical trials management software that counts contract research organisation PPD as an investor, raised $304m in series D funding yesterday at a $2.1bn valuation.
The round was co-led by Blackstone Growth, Tiger Global Management and GSR Ventures and backed by Sapphire Ventures and Western Technology Investment.
Founded in 2015 as Dermtap, Medable provides cloud-based software to conduct decentralised trials. It allows researchers tp remotely design and evaluate trials and manage and optimise volunteer recruitment, screening,…
